Alessandra Larocca
A5023517351- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- Ubiquitin and proteasome pathways
- Cancer Mechanisms and Therapy
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Phytochemical compounds biological activities
- Acute Myeloid Leukemia Research
- Multiple and Secondary Primary Cancers
- Cholinesterase and Neurodegenerative Diseases
- HIV/AIDS drug development and treatment
- Natural Compounds in Disease Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Computational Drug Discovery Methods
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Synthesis and Biological Activity
- Monoclonal and Polyclonal Antibodies Research
- Gastrointestinal motility and disorders
- Chemotherapy-induced cardiotoxicity and mitigation
University of Turin
2016-2025
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2015-2024
Bristol-Myers Squibb (Switzerland)
2022
Novartis (Switzerland)
2022
Sanofi (France)
2022
Janssen (Belgium)
2022
Amgen (United States)
2022
Janssen (Switzerland)
2022
GlaxoSmithKline (France)
2022
AbbVie (United States)
2022
Purpose The combination of bortezomib-melphalan-prednisone (VMP) is a new standard care for newly diagnosed multiple myeloma. This phase III study examined the efficacy four-drug bortezomib-melphalan-prednisone-thalidomide (VMPT) followed by maintenance with bortezomib-thalidomide (VMPT-VT) compared VMP treatment alone in untreated myeloma patients who are ineligible autologous stem-cell transplantation. Patients and Methods A total 511 were randomly assigned to receive nine cycles VMPT...
The European Myeloma Network provides recommendations for the management of most common complications multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as novel standard detection lytic lesions myeloma (grade 1A). patients with adequate renal function bone at diagnosis should be treated zoledronic acid or pamidronate Symptomatic without on can 1B), but its advantage not clear no...
PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), standard-of-care risk stratification model. Moreover, chromosome 1q gain/amplification (1q+) recently proved be a poor prognostic factor. In this study, we revised R-ISS by analyzing additive value each single feature, including 1q+. PATIENTS AND METHODS The European Myeloma Network,...
Bortezomib-melphalan-prednisone (VMP) has improved overall survival in multiple myeloma. This randomized trial compared VMP plus thalidomide (VMPT) induction followed by bortezomib-thalidomide maintenance (VMPT-VT) with patients newly diagnosed myeloma.We randomly assigned 511 who were not eligible for transplantation to receive VMPT-VT (nine 5-week cycles of VMPT 2 years VT maintenance) or without maintenance).In the initial analysis a median follow-up 23 months, complete response rate from...
Multiple myeloma management has undergone profound changes in the past thanks to advances our understanding of disease biology and improvements treatment supportive care approaches. This article presents recommendations European Myeloma Network for newly diagnosed patients based on GRADE system level evidence. All with symptomatic should undergo risk stratification classify International Staging System stage (level evidence: 1A) cytogenetically defined high- versus standard-risk groups (2B)....
ABSTRACT Introduction In the OPTIMISMM trial, pomalidomide/bortezomib/dexamethasone (PVd) significantly prolonged median progression‐free survival (PFS) versus bortezomib/dexamethasone (Vd) in lenalidomide‐exposed relapsed and refractory multiple myeloma (RRMM). We report final overall (OS) updated efficacy analyses. Methods Adults with RRMM who had 1–3 prior regimens, including lenalidomide (≥ 2 cycles), were assigned (1:1) to PVd or Vd. Primary endpoint: PFS. Prespecified secondary OS....
Purpose Continuous therapy (CT) prolongs progression-free survival 1 (PFS1; time from random assignment until the first progression or death), but chemotherapy-resistant relapse may negatively impact overall (OS). Progression-free 2 (PFS2; second death) represent an additional tool to estimate outcome. This study evaluates benefit of novel agent–based CT versus fixed duration (FDT) in patients with newly diagnosed myeloma. Methods We included enrolled onto three phase III trials that...
Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed refractory multiple myeloma (RRMM), population with an important unmet medical need.